Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2019

01-03-2019 | Pancreatic Cancer | PANCREATIC TUMORS

The Value of International Collaboration in Pancreatic Cancer Research: EURECCA

Author: Marc Besselink, MD, MSc, PhD

Published in: Annals of Surgical Oncology | Issue 3/2019

Login to get access

Excerpt

Pancreatic cancer is one of the worst types of cancer with a 5-year survival of 5–7%.1,2 Surgical resection combined with adjuvant chemotherapy is the optimal treatment option with 5-year survival rates around 20%. In recent years, interest has grown in newer treatment strategies, such as neoadjuvant chemoradiotherapy for (borderline) resectable pancreatic cancer. Recently, the first two multicenter, randomized trials from the Republic of Korea and the Netherlands suggested a doubled R0 resection rate and benefit in overall survival benefit with this approach.3,4 It is known that fairly large variations may exist between centers, regions, and countries in treatment and outcome of patient cancer. Typically, however, granularity is lacking to explore adequately the nature of these differences. …
Literature
1.
2.
Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, et al. EUROCARE-5 Working Group. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5. Eur J Cancer. 2015;51:2169–78.
3.
Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22.CrossRefPubMed
4.
Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. vTrials. 2016;17(1):127.
5.
Groen JV, Sibinga Mulder BG, van Eycken E, Valerianova Z, Borras JM, van der Geest LGM, et al. Differences in treatment and outcome of pancreatic adenocarcinoma stage I and II in the EURECCA Pancreas Consortium. Ann Surg Oncol. 2018;25(12):3492–501.CrossRefPubMed
6.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRefPubMed
7.
van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, et al. Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study. Ann Surg. 2019;269(1):10–7.CrossRefPubMed
Metadata
Title
The Value of International Collaboration in Pancreatic Cancer Research: EURECCA
Author
Marc Besselink, MD, MSc, PhD
Publication date
01-03-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-07127-4

Other articles of this Issue 3/2019

Annals of Surgical Oncology 3/2019 Go to the issue

HEPATOBILIARY TUMORS

The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy

Gastrointestinal Oncology

Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer

Gastrointestinal Oncology

Reply to: “Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?”, by Marino, Elisabetta et al.

Pancreatic Tumors

Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer

Translational Research and Biomarkers

MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection

Translational Research and Biomarkers

Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression